1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

T.Trarbach; J.Drevs; D.Strumberg; T.C.Gauler; V.Schneider; W.E.Eberhardt; B.Collins; M.Marotti; A.J.Swaisland

首页> 外文期刊>European Journal of Cancer Supplements >1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

【24h】

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

机译：1230 Cediranib（一种口服高效VEGF信号抑制剂）与saracatinib（AZD0530;一种有效的选择性Src抑制剂）组合：晚期实体瘤患者的I期开放标签研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
T.Trarbach; J.Drevs; D.Strumberg; T.C.Gauler; V.Schneider; W.E.Eberhardt; B.Collins; M.Marotti; A.J.Swaisland;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours [J] . Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Investigational New Drugs . 2012,第5期

机译：在晚期实体瘤患者中，西地那尼（一种口服的VEGF信号转导抑制剂）与口服Src抑制剂萨拉克拉替尼联合进行的I期开放标签研究
2. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. [J] . Tanja Trarbach, Beate Schultheis, Thomas C Gauler, Investigational new drugs. . 2012,第5期

机译：在晚期实体瘤患者中，西地那尼（一种口服的VEGF信号传导抑制剂）与口服Src抑制剂萨拉卡替尼联合使用的第一阶段开放标签研究。
3. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. [J] . Yamamoto N, Tamura T, Yamamoto N Cancer chemotherapy and pharmacology. . 2009,第6期

机译：在患有晚期实体瘤的日本患者中，西地尼布（RECENTIN）是一种强效且选择性的VEGFR信号抑制剂，其第一阶段，剂量递增和药代动力学研究。
4. PROTEIN EPITOPE MIMETICS: AN INNOVATIVE APPROACH TO THE DISCOVERY OF SELECTIVE AND HIGHLY POTENT SERINE PROTEASE INHIBITORS [C] . Odile Sellier, Francoise Jung, Steve J. DeMarco the European Peptide Symposium . 2007

机译：蛋白表位模拟方法：一种创新的选择性和高效丝氨酸蛋白酶抑制剂的方法
5. In search of selective and potent Golgi alpha-mannosidase II inhibitors as potential anticancer agents: Synthesis of 3-substituted-swainsonine analogs and preparation of immobilized swainsonine analogs on solid support. [D] . Guo, Luyi. 2003

机译：寻找选择性和有效的高尔基α-甘露糖苷酶II抑制剂作为潜在的抗癌药：3-取代-swainsonine类似物的合成和在固体支持物上固定的swainsonine类似物的制备。
6. Phase Ib/II open-label dose-escalation study of LGX818 an oral selective BRAF inhibitor in combination with MEK162 an oral MEK1/2 inhibitor in patients with BRAF V600-dependent advanced solid tumors: preliminary results [O] . Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, 2014

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的BRAF V600依赖性晚期实体瘤患者的Ib / II期开放标签剂量递增研究：初步结果
7. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results [O] . Richard Kefford, Ryan J Sullivan, Wilson H Miller, 2014

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的Ib / II期，开放标签，剂量递增研究，用于BRAF V600依赖性晚期实体瘤患者：初步结果

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

著录项

相似文献

相关主题

期刊订阅